Genetic approach to pediatric septic shock

Personalized Medicine

Volumn 5, Issue 3, 2008, Pages 249-263

  Wheeler, Derek S ^a   Wong, Hector R ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Epigenetics; Genomics; Pediatrics; Sepsis; Single nucleotide polymorphisms

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DROTRECOGIN; FC RECEPTOR IIA; FC RECEPTOR IIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; MANNOSE BINDING LECTIN; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN MD 2; RECOMBINANT ANTITHROMBIN III; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AMINO ACID SUBSTITUTION; BLOOD CLOTTING; CAUSE OF DEATH; CHILD CARE; CHILDHOOD MORTALITY; CLINICAL TRIAL; COMPLEMENT SYSTEM; EPIGENETICS; GENE DELETION; GENE EXPRESSION PROFILING; GENE INSERTION; GENETIC ASSOCIATION; GENETIC RISK; GENOMICS; HEALTH CARE COST; HEREDITY; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; INNATE IMMUNITY; MENINGOCOCCEMIA; MORBIDITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; URINARY TRACT INFECTION; VASCULAR ENDOTHELIUM;

EID: 44949083531     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.3.249     Document Type: Review

References (162)

1. Sepsis/septic shock. 2nd Edition. Pediatric Critical Care. Fuhrman BP, Zimmerman JJ (Eds). Mosby, St. Louis, USA, 1088 (1998).
2. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Balk RA: Sepsis syndrome: a valid clinical entity. Crit. Care Med. 17, 389-393 (1989).
3. American College of Chest Physicians, Society of Critical Care Medicine: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 20, 864-874 (1992).
4. Goldstein, B, Giroir B, Randolph A: International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr. Crit. Care Med. 6. 2-8 (2005).
5. Marshall JC: SIRS and MODS: What is their relevance to the science and practice of intensive care? Shock 14, 586-589 (2000).
6. Baue AE: A debate on the subject "Are SIRS and MODS impo!tant entities in the clinical evaluation of patients?" The con position. Shock 14, 590-593 (2000).
7. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 (2001).
8. Anderson RN, Smith BL: Deaths: Leading causes for 2001. Natl Vital Stat. Rep. 52, 1-85 (2003).
9. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003).
10. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC: The epidemiology of severe sepsis in children in the United States. Am. J. Respir. Crit. Care Med. 167, 695-701 (2003).
11. Proulx F, Fayon M, Farrell CA: Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 109, 1033-1037 (1996).
12. Watson RS, Carrillo JA: Scope and epidemiology of pediatric sepsis. Pediatr. Crit. Care Med. 2005, S3-S5 (2005).
13. Horbar JD, Onstad L, Wright E: Predicting mortality risk for infants weighing 501 to 1500 grams at birth: a National Institutes of Health Neonatal Research Network report. Crit. Care Med. 21, 12-18 (1993).
14. Schroder J, Kahlke V, Staubach KH, Zabel P, Stuber F: Gender differences in human sepsis. Arch. Surg. 133, 1200-1205 (1998).
15. Wichmann MW, Zellweger R, DeMaso CM, Ayala A, Chaudry IH: Mechanism of immunosuppression in males following trauma-hemorrhage. Critical role of testosterone. Arch. Surg. 131, 1186-1191; discussion 1191-1192 (1996).
16. Hazelzet J, Driessen GJA, Abboud P, Wheeler DS, Shanley TP, Wong HR: Sepsis In: Pediatric Critical Care Medicine: Basic Science and Clinical Evidence, Wheeler DS, Wong HR, Shanley TP (Eds). Springer-Verlag London Limited, London, UK, 1421-1444 (2007).
17. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003).
18. Thomas L: Germs. N. Engl. J. Med. 287, 553-555 (1972).
19. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM: Meningococcal disease. N. Engl. J. Med. 344, 1378-1388 (2001).
20. Giroir BP: Meningococcemia as a model for testing the hypothesis of antisepsis therapies. Crit. Care Med. 28, S57-S59 (2000).
21. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 319, 397-400 (1988).
22. Hatherill M, Tibby SM, Turner C, Ratnavel N, Murdoch IA: Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit. Care Med. 28, 2591-2594 (2000).
23. Deitch EA: Animal models of sepsis and shock: A review and lessons learned. Shock 9, 1-11 (1998).
24. Esmon CT: Why do animal models (sometimes) fail to mimic human sepsis? Crit. Care Med. 32, S219-S222 (2004).
25. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34, 1084-1093 (2002).
26. Osuchowski MF, Welch K, Siddiqui J, Remick DG: Circulating cytokine/ inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177, 1967-1974 (2006).
27. Ashare A, Powers LS, Butler NS, Doerschug KC, Monick MM, Hunninghake GW: Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am. J. Physiol. Lung Cell Mol. Physiol. 288, L633-L640 (2005).
28. Ronco C, Tetta C, Mariano F et al.: Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif. Organs 27, 792-801 (2003).
29. Levy MM, Fink MP, Marshall JC et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250-1256 (2003).
30. Denoix PX: Enquete permanent dans les centres anticancereaux. Bull. Inst. Natl Hyg. 1, 70-75 (1946).
31. Opal SM: Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr. Crit. Care Med. 6, S55-S60 (2005).
32. Cooke GS, Hill AV: Genetics of susceptibility to human infectious disease. Nat. Rev. Genet. 2, 967-977 (2001).
33. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW: Genetic and environmental influences on premature death in adult adoptees. N. Engl. J. Med. 318, 727-732 (1988).
34. Arcaroli J, Fessler MB, Abraham E: Genetic polymorphisms in sepsis. Shock 24, 300-312 (2005).
35. Waterer GW, Wunderink RG: Science review: Genetic variability in the systemic inflammatory response. Crit. Care 7, 308-314 (2003).
36. Holmes CL, Russell JA, Walley KR: Genetic polymorphisms in sepsis and septic shock. Role in prognosis and potential for therapy. Chest 124, 1103-1115 (2003).
37. Stuber F, Klaschik S, Lehmann LE, Schewe JC, Weber S, Book M: Cytokine promoter polymorphisms in severe sepsis. Clin. Infect. Dis. 41, S416-S420 (2005).
38. Matzinger P: An innate sense of danger. Semin. Immunol. 10, 399-415 (1998).
39. Akira S, Takeda K: Toll-like receptor signaling. Nat. Rev. Immunol. 4, 499-511 (2004).
40. Franchi L, McDonald C, Kanneganti TD, Amer A, Nunez G: Nucleotide-binding oligomerization domain-like receptors: Intracellular pattern recognition molecules for pathogen detection and host defense. J. Immunol. 177, 3507-3513 (2006).
41. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521 (2003).
42. El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR: Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol. Lett. 111, 36-44 (2007).
43. Arbour NC, Lorenz E, Schutte BC et al.: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25, 187-191 (2000).
44. Schwartz DA: The role of TLR4 in endotoxin responsiveness. J. Endotoxin Res. 7, 389-393 (2001).
45. Lorenz E, Mira JP, Frees KL, Schwartz DA: Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch. Intern. Med. 162, 1028-1032 (2002).
46. Agnese DM, Calvano JE. Hahm SJ et al.: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J. Infect. Dis. 186, 1522-1525 (2002).
47. Barber RC, Chang LY, Amoido BD et al.: Innate immunity SNPs are associated with risk for severe sepsis after burn injury. Clin. Med. Res. 4, 250-255 (2006).
48. Karoly E, Fekete A, Banki NF et al.: Heat shock protein 72 (HSPA1B) gene polymorphism and Toll-like receptor (TLR) 4 mutation are associated with increased risk of urinary tract infection in children. Pediatr. Res. 61, 371-374 (2007).
49. Read RC, Pullin J, Gregory S et al.: A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J. Infect. Dis. 184, 640-642 (2001).
50. Allen A, Obaro S, Bojang K et al.: Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr. Infect. Dis. J. 22, 1018-1019 (2003).
51. Hubacek JA, Stuber F, Frohlich D et al.: The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun. 1, 405-407 (2000).
52. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit. Care Med. 30, 969-973 (2002).
53. Heesen M, Bloemeke B, Schade U, Obertacke U, Majetschak M: The -260C->T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients. Intensive Care Med. 28, 1161-1163 (2002).
54. Gu W, Shan YA, Zhou J et al.: Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2. Ann. Surg. 246, 151-158 (2007).
55. Kutukculer N, Yenjay BS, Aksu G, Berdeli A: Armg753Gln polymorphism of the human toll-like receptor-2 gene in children with recurrent febrile infections. Biochem. Genet. 45, 507-514 (2007).
56. Tabel Y, Berdeli A, Mir S: Association of TLR2 gene Arg753Gly polymorphism with urinary tract infection in children. Int. J. Immunogenet. 34, 399-405 (2007).
57. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA: A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 68, 6398-6401 (2000).
58. Klevens RM, Morrison MA, Nadle J et al.: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298, 1763-1771 (2007).
59. Jefferies, C, O'Neill LA: Signal transduction pathway activated by Toll-like receptors. Mod. Asp. Immunobiol. 2, 169-175 (2002).
60. Picard C, Puel A, Bonnet M et al.: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076-2079 (2003).
61. Day NK, Tangsinmankong N, Ochs H et al.: Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J Pediatr. 144, 524-526 (2004).
62. van Deventer SJ: Cytokine and cytokine receptor polymorphisms in infectious disease. Intersive Care Med. 26 (Suppl. 1), S98-S102 (2000).
63. Mira JP, Cariou A, Grall F et al.: Association of TNF2, a TNF-α promoter polymorphism with septic shock susceptibility and mortality: a multicenter study. JAMA 282, 561-568 (1999).
64. Nadel S, Newport MJ, Booy R, Levin M: Variation in the tumor necrosis factor-α gene promoter region may be associated with death from meningococcal disease. J. Infect. Dis. 174, 878-880 (1996).
65. McArthur JA, Zhang Q, Quasney MW: Association between the A/A genotype at the lymphotoxin-α +250 site and increased mortality in children with positive blood cultures. Pediatr: Crit. Care Med. 3, 341-344 (2002).
66. Read RC, Cannings C, Naylor SC et al.: Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann. Intern. Med. 138, 534-541 (2003).
67. Endler G, Marculescu R, Starkl P et al.: Polymorphisms in the interleukin-1 gene cluster in children and young adults wih systemic meningococcemia. Clin. Chem. 52, 511-514 (2006).
68. Lehmbecher T, Bernig T, Hanisch M et al.: Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 19, 1745-1750 (2005).
69. Michalek, J, Svetlikova P, Fedora M et al.: Interleukin-6 gene variants and the risk of sepsis development in children. Hum. Immunol. 68, 756-760 (2007).
70. Balding J, Healy CM, Livingstone WJ et al.: Genomic polymorphic profiles in an Irish population with meningococcemia: is it possible to predict severity and outcome of disease? Genes Immun. 4, 533-540 (2003).
71. Artifoni L, Negrisolo S, Montini G et al.: Interleukin-8 and CKCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis. J. Urol. 177, 1102-1106 (2007).
72. Marshall JC: Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit. Care Med. 29, S99-S106 (2001).
73. Abraham E, Singer M: Mechanisms of sepsis-induced organ dysfunction. Crit. Care Med. 35, 2408-2416 (2007).
74. Remick DG: Pathophysiology of sepsis. Am. J. Pathol. 170, 1435-1444 (2007).
75. Warren BL, Eid A, Singer P et al.: Caring for the critically III patient. High-dose. antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286, 1869-1878 (2001).
76. Abraham E, Reinhart K, Opal S et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238-247. (2003).
77. Bernard GR, Vincent JL, Laterre PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
78. Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP: Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit. Care Med. 32, S313-S319 (2004).
79. Erikkson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl Acad. Sci. USA 92, 1851-1855 (1995).
80. Westendorp RG, Hottenga JJ, Slagboom PE: Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 354, 561-563 (1999).
81. Haralambous E, Hibberd ML, Hermans PWM, Ninis N, Nadel S, Levin M: Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit. Care Med. 31, 2788-2793 (2003).
82. Geishofer G, Binder A, Muller M et al.: 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcemia. Eur. J. Pediatr. 164, 486-490 (2005).
83. Hemians PWM, Hibberd ML, Booy R et al.: G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 354, 556-560 (1999).
84. van der Pol W, van de Winkel JG: IgG receptor polymorphisms: risk factors for disease. Immunogenetics 48, 222-232 (1998).
85. van Sorge NM, van der Pol WL, van de Winkel JG: FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61, 189-202 (2003).
86. Bredius RG, Derkx BH, Fijen CA et al.: Fc γ receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J. Infect. Dis. 170, 848-853 (1994).
87. Domingo P, Muniz-Diaz E, Baraldes MA et al.: Associations between Fc γ receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am. J. Med. 112, 19-25 (2002).
88. Platonov AE, Kuijper EJ, Vershinina IV et al.: Meningococcal disease and polymorphism of FcγRIIa (CD32) in late complement component-deficient individuals. Clin Exp. Immunol. 111, 97-101 (1998).
89. Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van de Winkel JG, Kuijper EJ: Association of human Fc γ RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin. Infect. Dis. 27, 746-750 (1998).
90. van der Pol WL, Huizinga TW, Vidarsson G et al.: Relevance of Fcγ receptor and interleukin-10 polymorphisms for meningococcal disease. J. infect. Dis. 184, 1548-1555 (2001).
91. Fijen CA, Bredius RG, Kuijper EJ: Polymorphism of IgG Fc receptors in meningococcal disease. Ann. Intern. Med. 119, 636 (1963).
92. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM: Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30, 25-28 (2000).
93. Sanders LA, van de Winkel JG, Rijkers GT: Fcγ receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J. Intect. Dis. 170, 854-861 (1994).
94. Yuan FF, Wong M, Pererva N et al.: FcγRIIA polymorphisms in Streptococcus pneumoniae infection. Immunol. Cell Biol. 81, 192-195 (2003).
95. Kuhlman, M, Joiner K, Ezekowitz RA: The human mannose-binding protein functions as an opsonin. J. Exp. Med. 169, 1733-1745 (1989).
96. Summerfield JA, Sumiya M, Levin M, Turner MW: Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 314, 1229-1232 (1997).
97. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M: Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 353, 1049-1053 (1999).
98. Koch A, Melbye M, Sorensen P et al.: Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 285, 1316-1321 (2001).
99. Gomi K, Tokue Y, Kobayashi T et al.: Mannose-binding lectin gene polymorphism is a modulating factor in repeated respiratory infections. Chest 126, 95-99 (2004).
100. Roy S, Knox K, Segal S et al.: MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 359, 1569-1573 (2002).
101. Fidler KJ, Wilson P Davies JC, Turner MW, Peters MJ, Klein NJ: Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. Intensive Care Med. 30, 1438-1445 (2004).
102. Weiss J: Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function, and regulation in host defence against Gram-negative bacteria. Biochem. Soc. Trans. 31, 785-790 (2003).
103. Levin M, Quint PA, Goldstein B et al.: Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomized trial. Lancet 356, 961-967 (2000).
104. Michalek J, Svetlikova P, Fedora M et al.: Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med. 33, 2158-2164 (2007).
105. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphisin in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346 (1990).
106. Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/ deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 20, 1433 (1992).
107. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F: Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem. J. 290(Pt 1), 33-40 (1993).
108. Tiret L, Rigat B, Visvikis S et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. 51, 197-205 (1992).
109. Harding D, Baines PB, Beull D et al.: Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/ deletion polymorphism. Am. J. Respir. Crit. Care Med. 165, 1103-1106 (2002).
110. Vitali SH, Randolph AG: Assessing the quality of case-control association studies on the genetic basis of sepsis. Pediatr. Crit. Care Med. 6, S74-S77 (2005).
111. Clark MF, Baudouin SV: A systematic review of the quality of genetic association studies in human sepsis. Intendve Care Med. 32, 1706-1712 (2006).
112. Peters DL, Barber RC, Flood EM, Garner HR, O'Keefe GE: Methodologic quality and genotyping reproducibility in studies of turnor necrosis factor -308 G->A single nucleotide polymorphism, and bacterial sepsis: Implications for studies of complex traits. Crit. Care Med. 31, 1691-1696 (2003).
113. Fisch NJ: Searching for genetic determinants in the new millenium. Nature 405, 847-856 (2000).
114. Daly AK: Candidate gene case-control association studies: advantages and potential pitfalls. Br. J. Clin. Pharmacol. 52, 489-499 (2001).
115. Silverman EK: Case-control association studies for the genetics of complex respiratory diseases. Am. J. Respir. Cell Mol. Biol. 22, 645-648 (2000).
116. Estivill X, Armengol L: Copy number variants and common disorders: Filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet. 3, 1787-1799 (2007).
117. Shanley TP, Hallstrom C, Wong HR: Sepsis, In: Pediatric Critical Cam Medicine, Fuhrman BP, Zimmerman JJ (Eds). Mosby, St. Louis, MO, USA, 1474-1493 (2006).
118. Cobb JP, Mindrinos MN, Miller-Graziano C et al.: Application of genome-wide expression analysis to human health and disease. Proc Natl Acad. Sci. USA 102, 4801-4806 (2005).
119. Wong HR: Pediatric septic shock treatment: new clues from genomic profiling. Pharmacogenomics 8, 1287-1290 (2007).
120. Nadon R, Shoemaker J: Statistical issues with microarrays: processing and analysis. Trends Genet. 18, 265-271 (2002).
121. Wilkes T, Laux H, Foy CA: Microarray data quality - review of current developments. Omics 11, 1-13 (2007).
122. Calvano SE, Xiao W, Richards DR et al.: A network-based analysis of systemic inflammation in humans. Nature 437, 1032-1037 (2005).
123. Chinnaiyan AM, Huber-Lang M, Kumar-Sinha C et al.: Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. Am. J. Pathol. 159, 1199-1209 (2001).
124. Pachot A, Lepape A, Vey S, Bienvenu J, Mougin B, Monneret G: Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol. Lett. 106, 63-71 (2006).
125. Prucha M, Ruryk A, Boriss H et al.: Expression profiling: toward an application in sepsis diagnostics. Shock 22, 29-33 (2004).
126. Ramillo O, Allman W, Chung W et al.: Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109, 2066-2077 (2007).
127. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC: The use of gene-expression profiling to identify candidate genes in human sepsis. Am. J. Respir. Crit. Care Med. 176, 676-684 (2007).
128. Wong HR, Shanley TP, Sakthivel B et al.: Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol. Genomics 30, 146-155 (2007).
129. Shanley TP, Cvijanovich N, Lin R et al.: Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock. Mol. Med. 13, 495-508 (2007).
130. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003).
131. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA: Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J. Immunol. 174, 3765-3772 (2005).
132. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med. 25, 556-566 (1999).
133. Hotchkiss RS, Swanson PE, Knudson CM et al.: Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol. 162, 4148-4156 (1999).
134. Hotchkiss RS, Tinsley KW, Karl IE: Role of apoptotic cell death in sepsis. Scand J. Infect. Dis. 35, 585-592 (2003).
135. Hotchkiss RS, Coopersmith GM, Karl IE: Prevention of lymphocyte apoptosis - a potential treatment of sepsis? Clin. Infect. Dis. 41(Suppi. 7), S465-S469 (2005).
136. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE: Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol. 174, 5110-5118 (2005).
137. Hotchkiss RS, McConnell KW, Bullok K et al.: TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol. 176, 5471-5477 (2006).
138. Ayala A, Chaudry IH: Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes, and apoptosis. Shock 6(Suppl. 1), S27-S38 (1996).
139. Unsinger J, Herndon JM, Davis CG, Muenzer JT, Hotchkiss RS, Ferguson TA: The role of TCR engagement and activation-induced cell death in sepsis-induced T cell apoptosis. J. Immunol. 177, 7968-7973 (2006).
140. Hotchkiss RS, Swanson PE, Freeman BD et al.: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27, 1230-1251 (1999).
141. Docke WD, Randow F, Syrbe U et al.: Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3, 678-681 (1997).
142. Monneret G, Finck ME, Venet F et al.: anti-inflanunatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol. Lett. 95, 193-198 (2004).
143. Pachot A, Monneret G, Brion A et al.: Messenger RNA expression of major histocompatibility complex class II genes in whole blood from sepitc shock patients. Crit. Care Med. 33, 31-38; discussion 236-237 (2005).
144. Pangault C, Le Tulzo Y, Tattevin P, Guilloux V, Bescher N, Drenou B: Down-mbdulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Crit. Care Med. 34, 1193-1201 (2006).
145. Rink L, Haase H: Zinc homeostasis and immunity. Trends Immunol. 28, 1-4 (2007).
146. Ibs KH, Rink L: Zinc-altered immune function. J. Nutr. 133, 1452S-1426S (2003).
147. Fraker PJ, King LE: Reprogramming of the immune system during zinc deficiency. Annu. Rev. Nutr. 24, 277-298 (2004).
148. Hollick JB, Dorweiler JE, Chandler VL: Paramutation and related allelic interactions. Trends Genet. 13, 302-308 (1997).
149. Brannan CI, Bartolomei MS: Mechanisms of genomic imprinting. Curr. Opin. Ganet. Dev. 9, 164-170 (1999).
150. Sarge KD, Park-Sarge OK: Gene bookmarking: keeping the pages open. Trends Biochem. Sci. 30, 605-610 (2005).
151. Chow JC, Yen Z, Ziesche SM, Brown CJ: Silencing of the mammalian X chromosome. Annu. Rev. Genomics Hum. Genet. 6, 69-92 (2005).
152. Hochedlinger K, Jaenisch R: Nuclear reprogramming and pluripotency. Nature 441, 1061-1667 (2006).
153. Weiler KS, Wakimoto BT: Heterochromatin and gene expression in Drosophila. Annu. Rev. Genet. 29, 577-605 (1995).
154. Wu CT, Morris JR: Transvection and other homology effects. Curr. Opin. Genet. Dev. 9, 237-246 (1999).
155. Berger SL: The complex Language of chromatin regulation during transcription. Nature 447, 407-412 (2007).
156. Wen H, Dou Y, Hogaboam CM, Kunkel SL: Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression following a severe innate immune response. Blood 111(4), 1797-1804 (2007).
157. Wen H, Schaller MA, Dou Y, Hogaboam CM, Kunkel SL: Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes. J. Leukoc. Biol. 83(3), 439-446 (2007).
158. Ansel KM, Djuretic I, Tanasa B, Rao A: Regulation of Th2 differentiation and Il4 locus accessibility. Annu. Rev. Immunol. 24, 607-656 (2006).
159. Chan C, Li L, McCall CE, Yoza BK: Endotoxin tolerance disrupts chromatin remodeling and NF-κB transactivation at the IL-1β promoter. J. Immunol. 175, 461-468 (2005).
160. El Gazzar M, Yoza BK, Hu YJ, Cousart SL, McCall CE: Epigenetic silencing of tumor necrosis factor α during endotoxin tolerance. J. Biol. Chem. 282, 26857-26864 (2007).
161. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972-978 (2007).
162. Berger SL: The complex language of chromatin regulation during transcription. Nature 447, 407-412 (2007).